Event

Pulmonary hypertension (PH) and idiopathic pulmonary fibrosis (IPF) are progressive diseases with high mortality rates and poor treatment options, both of which share incredible number of pathological molecular mechanisms with human cancers. This offers exciting opportunity to employ cancer-specific strategies and/or re-purpose anti-cancer agents for treatment of those diseases. This session will provide overview of major pro-proliferative signaling pathways that act as “central signaling hubs” in PH, IPF and cancer, summarize recent progress in cellular, pre-clinical and clinical studies focused on cancer-shared abnormalities, and discuss the opportunities for re-purposing or cross-development of anti-cancer agents that can be used in improving PH and IPF treatment.